INTRODUCTION

Interferons are cytokines with antiviral, anti-proliferative and immuno-modulation property with ability to interfere with viral replication within host cells. They activate immune cells such as Natural Killer (NK) and cytotoxic-T cells and increase the ability of uninfected host cells to resist new infections by virus, by producing certain proteins known as interferon stimulated genes.\(^1\) Interferon-alpha (IFN-alpha) therapy with or without other antiviral agents is standard care of treatment in patients with hepatitis-C.

We report a case of a patient with hepatitis-C, treated with IFN-alpha who developed ocular complication.

CASE REPORT

A 30-year-old male presented with gradual decrease in vision in his both eyes after the use of interferon alpha for his hepatitis-C. Ocular examination of patient included, Best Corrected Visual Acuity (BCVA), fundus photographs, Fundus Fluorescein Angiography (FFA) and Optical Coherence Tomography (OCT). His BCVA was recorded as 6/18 in the right eye and 6/12 in the left eye. The anterior segments were unremarkable, with normal intraocular Pressure (IOP) in his both eyes. Both fundi revealed the presence of bilateral Choroidal Neovascularization (CNV), confirmed on FFA and OCT. To the best of authors’ knowledge, simultaneous presence of CNV in both eyes is not reported in the literature.

Key Words: Bilateral choroidal neovascularization. Interferon alpha. Hepatitis-C.
The patient was advised and given injection Bevacizumab (Avastin) 1.25 mg intravitreally in his both eyes under sterile condition in operating room.

**DISCUSSION**

To the best of authors' knowledge, simultaneous presence of CNV in both eyes after IFN-alpha therapy is not reported in the literature previously. Retinal ischemia has been a common manifestation of IFN treatment in patients with hepatitis-C, characterized by presence of microaneurysms, retinal haemorrhages and cotton-wool spots.\(^2\) The prevalence of retinopathy is variable among different studies. Panetta suggested an overall low occurrence of retinopathy at 3.8% in 180 patients treated with IFN-alpha.\(^3\) Kadayifcilar and co-workers evaluated 36 patients with chronic active hepatitis receiving IFN-alpha for one year and found 15 patients (42%) having retinopathy with cotton-wool formation and splinter haemorrhages.\(^4\)

The underlying patho-physiology for IFN induced retinopathy is not known. The presence of retinal haemorrhages and cotton-wool areas suggest an ischemic response. The possible mechanism for retinopathy is believed to be due to immune system dysfunction, deposition of immune complexes in the retinal vessels and increase adhesions of activated leucocytes.\(^5\) Similar mechanism can be argued for choroidal ischemia resulting in Choroidal Neovascularization (CNV). The elevated level of Vascular Endothelial Growth Factor (VEGF) after IFN-alpha therapy has also been reported with correlation to choroidal ischemia and CNV.\(^6\) Hepatitis-C itself is believed to cause an increase in photocoagulated phospholipids resulting in hypercoagulable state, especially when combined with IFN-alpha treatment with production of thrombogenic auto-antibodies.\(^7\)

Interestingly as IFN has angiostatic property and inhibits the proliferation and migration of vascular endothelial cells, it has also been used to treat CNV in age-related macular degeneration. However, results of these studies are inconclusive with a need for further randomized trials.\(^8\)

Ocular ischemic changes are more reported in patients with history of DM, HTN and with increased lipids and it is also believed that these changes settle down with termination of IFN-alpha therapy.\(^9\) Choroidal neovascularization in one eye after IFN-alpha therapy has already been reported.\(^10\) Other rare findings related to IFN-alpha therapy include anterior ischemic optic neuropathy, papilloedema, retinal artery occlusion, central retinal vein occlusion and pan-uveitis.\(^4\) This patient last used IFN-alpha 6 months ago and did not have any other associated risk factors, such as DM, HTN or raised lipids.

**REFERENCES**